Tag Archives: Tina Shogen
Phase III Program ofONCONASE for The Treatment of Patients with Unresectable Malignant Mesothelioma
SOURCE: Alfacell Corporation BLOOMFIELD, N.J., April 3 /PRNewswire-FirstCall/ — Alfacell Corporation today announced that the encouraging survival data from its Phase II multicenter trial of ONCONASE®, led the Company to conduct a Phase III program which included the evaluation of ONCONASE as a single agent at 33 centers across the United States and the combination [...]
Posted in Pharmaceutical News
Tagged Alfacell Corporation, Asbestos, ASCO, BLOOMFIELD, CALGB, Europe, Mesothelioma, NDA, ONCONASE, symptoms, Tina Shogen, Treatment Target Group, TTG
Leave a comment
